B2134
Sigma

2-Bromo-α-ergocryptine methanesulfonate salt

solid

zoom

1 of 1

Synonym

(+)-Bromocriptine methanesulfonate salt

Bromocriptine mesylate salt

(+)-2-Bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′-18-trione methanesulfonate salt

Molecular Formula

C₃₂H₄₀BrN₅O₅ · CH₄SO₃

Molecular Weight

750.70

CAS Number

22260-51-1

Beilstein Registry Number

4115238

MDL number

MFCD00069218

PubChem Substance ID

24277885

EG/EC Number

244-881-1

Expand/Collapse All

Descriptions

Biochem/physiol Actions

Agonist at D₂ and D₃ dopamine receptors; inhibits prolactin secretion.

Properties

form

solid

optical activity

[α]20/D +95°, c = 1 in methanol: methylene chloride (1:1)(lit.)

color

white

solubility

H₂O: 0.8 mg/mL

ethanol: 23 mg/mL

Gene Information

human ... DRD2(1813), DRD3(1814), PRL(5617)

storage temp.

2-8°C

References

Reference

Zhang, Y., Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. Metabolism 48, 1033, (1999) abstract

Velasco, M. and Luchsinger, A., Dopamine: pharmacologic and therapeutic aspects. Am. J. Ther. 5, 37-43, (1996)

Geurts, M., et al., Dopamine receptor-modulated [³⁵S]GTPγS binding in striatum of 6-hydroxydopamine-lesioned rats. Brain Res. 841, 135-142, (1999) abstract

Perachon, S., et al., Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D₁, D₂ and D₃ receptors. Eur. J. Pharmacol. 366, 293, (1999) abstract

Merck

Merck 13,1400

Safety

Safety Statements

22-24/25

WGK Germany

RTECS

KE1595000

3-10